Marathon, Genetics, Inflammation and the Cardiovascular System: MAGIC-Trial
The purpose of the study is to determine the myocardial function and vascular adaptation after strenuous exercise in association with genotype/polymorphisms. We aim to investigate the effects of extreme endurance exercise on the cardiovascular system. Furthermore, the role of the inflammatory response and adaptive mechanisms of the vasculature are examined. Subclinical injuries to the myocardium and vascular wall are being investigated.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Investigation of Myocardial Function and Vascular Adaptation in Association With Genotype in Marathon Runners|
- E/A ratio [ Time Frame: pre-, post-, one day follow-up ] [ Designated as safety issue: Yes ]
- LV twist [ Time Frame: pre-, post-, one day follow-up ] [ Designated as safety issue: Yes ]
|Study Start Date:||September 2008|
|Estimated Study Completion Date:||June 2013|
|Primary Completion Date:||October 2008 (Final data collection date for primary outcome measure)|
Behavioral: Munich Marathon
Regular exercise leads to an improvement of cardiovascular risc factors in patients with coronary heart disease, atherosclerosis and metabolic disorders. Aerobic exercise has anti-inflammatory effects. In contrast, the exertional exercise of marathon running causes an acute pro-inflammatory impulse. This may lead to myocardial injury and, in case of preexisting plaques, may result in plaque rupture and acute myocardial infarction.
We aim to define the critical role of inflammatory markers and cardiovascular risc factors as a predictor of an increased risk for myocardial and endothelial dysfunction in marathon runners.
Diagnostic tools include measurements of augmentation index (AIx), arteriolar-venular ratio (AVR) and, for the first time, 2D and 3D echocardiographic measurements such as TDI-imaging and speckle tracking. Inflammatory markers include c-reactive protein (CRP), interleukins and tumor necrosis factor. Additionally, cardiovascular markers are measured. All variations are analysed on the basis of genotype characteristics/polymorphisms.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00845286
|Contact: Hanssen Henner, MD||0049-89-289244 ext email@example.com|
|Contact: Scherr Johannes, MD||0049-89-289244 ext firstname.lastname@example.org|
|Department of Prevention and Sports medicine||Recruiting|
|Munich, Bavaria, Germany, 80809|
|Contact: Hanssen Henner, MD 0049-89-289244 ext 31 email@example.com|
|Contact: Scherr Johannes, MD 0049-89-289-244 ext 31 firstname.lastname@example.org|
|Principal Investigator: Hanssen Henner, MD|
|Sub-Investigator: Scherr Johannes, MD|